Hudson Bay Capital Management
KYTX icon

Hudson Bay Capital Management’s Kyverna Therapeutics KYTX Stock Holding History

Hudson Bay Capital Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-71,059
Closed -$613K – 1735
2026
Q1 		$613K Sell
71,059
-17,494
-20% -$146K ﹤0.01% 951
2025
Q4 		$832K Buy
+88,553
New +$657K ﹤0.01% 818
2024
Q4 		– Sell
-52,035
Closed -$254K – 1152
2024
Q3 		$254K Buy
+52,035
New +$401K ﹤0.01% 745
2024
Q2 		– Sell
-50,000
Closed -$1.24M – 971
2024
Q1 		$1.24M Buy
+50,000
New +$1.4M 0.01% 524

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Hudson Bay Capital Management's KYTX Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of Kyverna Therapeutics (KYTX) in Q2 2026, closing a stake of 71,059 shares — an estimated $613K sold.

Hudson Bay Capital Management first reported a position in KYTX in Q1 2024 and held it in 4 quarters. The position peaked at $1.24M in Q1 2024. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Hudson Bay Capital Management reported no remaining Kyverna Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 71,059 Kyverna Therapeutics shares in Q2 2026, an estimated $613K.
  • Hudson Bay Capital Management first reported a position in Kyverna Therapeutics in Q1 2024 and held it in 4 quarters.
  • Hudson Bay Capital Management's Kyverna Therapeutics position peaked at $1.24M in Q1 2024.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.